The Effect of LDL557 on Improving Degenerative Arthritis in the Elderly

Launched by CHUNG SHAN MEDICAL UNIVERSITY · Oct 23, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment called LDL557, which comes in capsule form, to see if it can help improve joint pain and inflammation in older adults with early-stage degenerative arthritis. The goal is to find a better way to protect joints and reduce discomfort for people dealing with arthritis.

The trial is not yet recruiting participants, but it aims to involve adults aged between 16 and 92 years. To be eligible, participants should have a body mass index (BMI) between 18 and 40 and show early signs of arthritis based on specific medical tests. However, individuals with certain health issues, like diabetes, those who smoke or drink heavily, and women who are pregnant or breastfeeding, cannot participate. If you join this study, you can expect to monitor any changes in your joint pain and inflammation after taking the capsules. This trial represents an exciting opportunity for those looking for new options to manage their arthritis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • BMI 18-40 kg/m2;
• • Those with early stage degenerative arthritis symptoms judged by X-ray to be Kellgren-Lawrence Grading Scale level 1 or 2, and the physician determines that long-term treatment is not needed or WOMAC score\>2.0 or WOMAC total scale score\>12 or VAS score ≦3.
• Exclusion Criteria:
• • Smoking
• • alcoholism
• • diabetes
• • breastfeeding women and pregnant women.
• • Those consuming dietary supplements were excluded.
• • Those who use non-steroidal anti-inflammatory analgesics and those who have had joint surgery.
• • Rheumatoid arthritis.
• • Those who have had joint injections within 6 months.
• • Those with cardiovascular and cerebrovascular, rheumatoid or mental diseases.
• • Patients undergoing cancer treatment.